The Nordic region has emerged as one of Europe's most dynamic biologics ecosystems, with 400+ companies spanning therapeutic development, contract services, and enabling technologies. This directory profiles the complete landscape, from global giants like Novo Nordisk (market cap $309B) and AstraZeneca to clinical-stage innovators and specialised CDMOs. The region's unique advantages include world-class research infrastructure, generous R&D incentives, single-payer healthcare systems enabling clinical trials, and unique population genetics databases.